28031240|t|Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide - resistant Glioblastoma Cell Line
28031240|a|Temozolomide - resistant (TMZ - R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed. The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ - resistant U87 cell line. The growth-inhibitory effect of the combination treatment was significant against the TMZ - R U87 cell line (IC50: 78 μM for STX-0119, 30.5 μM for rapamycin and 11.3 μM for combination of the two). Western blotting analysis demonstrated that the inhibitory effect of STX-0119 on S6 and 4E-BP1 activation through regulation of YKL-40 expression occurred in addition to the inhibitory effect of rapamycin against the mTOR pathway. These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ - resistant relapsed gliomas.
28031240	0	11	Combination	T080	C0205195
28031240	17	22	STAT3	T116,T123	C0253050
28031240	23	32	Inhibitor	T120	C0243077
28031240	40	54	mTOR Inhibitor	T121	C2746052
28031240	65	77	Temozolomide	T109,T121	C0076080
28031240	80	89	resistant	T038	C0013203
28031240	90	102	Glioblastoma	T191	C0017636
28031240	103	112	Cell Line	T025	C0007634
28031240	113	125	Temozolomide	T109,T121	C0076080
28031240	128	137	resistant	T038	C0013203
28031240	139	142	TMZ	T109,T121	C0076080
28031240	145	146	R	T038	C0013203
28031240	148	160	glioblastoma	T191	C0017636
28031240	182	187	treat	T061	C0087111
28031240	222	232	resistance	T038	C0013203
28031240	262	273	combination	T080	C0205195
28031240	274	283	treatment	T061	C0087111
28031240	287	292	STAT3	T116,T123	C0253050
28031240	293	302	inhibitor	T120	C0243077
28031240	304	312	STX-0119	T109,T121	C3177942
28031240	319	328	rapamycin	T109,T195	C0072980
28031240	370	373	TMZ	T109,T121	C0076080
28031240	376	385	resistant	T038	C0013203
28031240	386	399	U87 cell line	T025	C0007634
28031240	405	429	growth-inhibitory effect	T043	C0007613
28031240	437	448	combination	T080	C0205195
28031240	449	458	treatment	T061	C0087111
28031240	487	490	TMZ	T109,T121	C0076080
28031240	493	494	R	T038	C0013203
28031240	495	508	U87 cell line	T025	C0007634
28031240	510	514	IC50	T081	C0600495
28031240	526	534	STX-0119	T109,T121	C3177942
28031240	548	557	rapamycin	T109,T195	C0072980
28031240	574	585	combination	T080	C0205195
28031240	599	624	Western blotting analysis	T059,T063	C0005863
28031240	647	664	inhibitory effect	T043	C0007613
28031240	668	676	STX-0119	T109,T121	C3177942
28031240	680	682	S6	T116,T126	C0073337
28031240	687	693	4E-BP1	T116,T123	C0254260
28031240	694	704	activation	T044	C0014429
28031240	713	723	regulation	T045	C0017263
28031240	727	733	YKL-40	T116,T123	C0528649
28031240	734	744	expression	T045	C1171362
28031240	773	790	inhibitory effect	T043	C0007613
28031240	794	803	rapamycin	T109,T195	C0072980
28031240	816	828	mTOR pathway	T044	C1515673
28031240	861	866	STAT3	T116,T123	C0253050
28031240	867	874	pathway	T044	C1704259
28031240	878	893	associated with	T080	C0332281
28031240	898	921	mTOR downstream pathway	T044	C1515673
28031240	934	948	YKL-40 protein	T116,T123	C0528649
28031240	958	969	combination	T080	C0205195
28031240	970	977	therapy	T061	C0087111
28031240	985	990	STAT3	T116,T123	C0253050
28031240	991	1000	inhibitor	T120	C0243077
28031240	1005	1014	rapamycin	T109,T195	C0072980
28031240	1052	1072	therapeutic approach	T061	C0087111
28031240	1081	1084	TMZ	T109,T121	C0076080
28031240	1087	1096	resistant	T038	C0013203
28031240	1097	1105	relapsed	T067	C0035020
28031240	1106	1113	gliomas	T191	C0017638